In Brief: Product liability
This article was originally published in The Gray Sheet
Executive Summary
Product liability: Senate fails twice to invoke cloture May 4 on a substitute amendment offered by Sen. Slade Gorton (R-Wash.) to the product liability bill, HR 956. The substitute is a heavily amended version of the original Gorton/Rockefeller bill (S 565). The first vote (46-53) to limit debate fell short of the necessary 60 votes, with two Democrats, Sens. Joseph Lieberman (Conn.) and James Exon (Neb.), breaking ranks. In the second vote (47-52), Republican Strom Thurmond (S.C.) switched his vote in favor of cloture. Senate Majority Leader Robert Dole (R-Kan.) indicated before the votes that in the event of no cloture, another Gorton/Rockefeller amendment would be considered as a substitute; GOP leadership indicated that the measure is likely to be considered again the week of May 8...
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.